DrugPatentWatch Database Preview
Lannett Co Inc Company Profile
What is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?
LANNETT CO INC has one hundred and thirty-one approved drugs.
There is one US patent protecting LANNETT CO INC drugs.
There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and five supplementary protection certificates in twelve countries.
Summary for Lannett Co Inc
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 101 |
| Ingredients: | 94 |
| NDAs: | 131 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | SUMATRIPTAN | sumatriptan | SPRAY;NASAL | 204841-002 | Feb 19, 2016 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | OXYBUTYNIN CHLORIDE | oxybutynin chloride | SYRUP;ORAL | 076682-001 | Dec 28, 2004 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | HYDROMORPHONE HYDROCHLORIDE | hydromorphone hydrochloride | TABLET;ORAL | 077471-002 | Dec 9, 2009 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | CLEMASTINE FUMARATE | clemastine fumarate | SYRUP;ORAL | 074884-001 | Dec 17, 1997 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Lannett Co Inc | METADATE ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 040306-001 | Oct 20, 1999 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Lannett Co Inc | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | CAPSULE;ORAL | 203823-001 | Aug 1, 2014 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | DOXYCYCLINE | doxycycline | TABLET;ORAL | 065285-003 | Jul 30, 2008 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
International Patents for Lannett Co Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 0234234 | ➤ Sign Up |
| European Patent Office | 2103307 | ➤ Sign Up |
| Canada | 2426883 | ➤ Sign Up |
| European Patent Office | 2269605 | ➤ Sign Up |
| European Patent Office | 2286815 | ➤ Sign Up |
| Portugal | 2103307 | ➤ Sign Up |
| European Patent Office | 1328251 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Lannett Co Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0609 | Netherlands | ➤ Sign Up | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| 2014000088 | Germany | ➤ Sign Up | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
| C/GB98/043 | United Kingdom | ➤ Sign Up | PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512 |
| 90027-7 | Sweden | ➤ Sign Up | PRODUCT NAME: MONTELUKAST, R-(E)-1-1-3-2-(7-KLOR-2KINOLINYL)-ETENYL)-FENYL)-3-(2-(1-HYDROXI-1-METYLETYL)-FENYL)-PROPYL)-TIO)METYL)-CYKLOPROPANAETTIKSYRA, ELLER ETT FARMACEUTISKT GODDTAGBART SALT DAERAV, FOERETRAEDESVIS NATRIUMSALTET; NAT REG./DATE: 13944 19880111; FIRST REG.: FI EG 12766 19970825 |
| C/GB96/004 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811 |
| C/GB01/044 | United Kingdom | ➤ Sign Up | PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320 |
| C/GB96/056 | United Kingdom | ➤ Sign Up | PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
